Molecular Partners AG (MOLN)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Molecular Partners AG (MOLN) is down 9.4% since the beginning of the year. At $4 per share, MOLN is trading 26.3% below its 52-week high of $5. Investors who bought $1,000 worth of MOLN shares 5 years ago would now be looking at an investment worth $204.

Molecular Partners AG (MOLN) has returned -9.37% so far this year and 1.54% over the past 12 months.

Based on dividend-adjusted daily data since Jun 16, 2021, MOLN's average daily return is -0.01%, while the average monthly return is -0.73%.

Historically, 36% of months were positive and 64% were negative. The best month was Jun 2024 with a return of +100.8%, while the worst month was Apr 2022 at -60.8%. The longest winning streak lasted 2 consecutive months, and the longest losing streak was 7 months.

On a daily basis, MOLN closed higher 42% of trading days. The best single day was Oct 21, 2024 with a return of +39.2%, while the worst single day was Apr 27, 2022 at -37.4%.

Molecular Partners AG has an annualized alpha of -8.46%, beta of 0.50, and R2 of 0.01 versus S&P 500 Index. Calculated based on daily prices since June 16, 2021.

• This stock participated in 187.86% of S&P 500 Index downside but only 37.40% of its upside - more exposed to losses than it benefited from rallies.
• Beta of 0.50 may look defensive, but with R2 of 0.01 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R2 of 0.01 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

MOLN ranks 43 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Molecular Partners AG. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Molecular Partners AG was 89.59%, occurring on Apr 19, 2024. The portfolio has not yet recovered.

The current Molecular Partners AG drawdown is 87.61%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Molecular Partners AG over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Molecular Partners AG is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.